[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100261699":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":57,"collaborators":59,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-Flutemetamol & 18F-FDG PET scans",null,"All study participants will be assessed by PET scan with 18F-Flutemetamol \\& 18F-FDG PET scans.",[13],"Procedure: 18F-Flutemetamol & 18F-FDG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","18F-Flutemetamol & 18F-FDG","Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.",[9],[21],{"name":22,"affiliation":23,"role":24},"Jose Luis Molinuevo, MD, PhD","Scientific Director","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Karine Fauria, PhD","CONTACT","933160990","kfauria@fpmaragall.org",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},"Carolina Herrero","cherrero@fpmaragall.org",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"BarcelonaBeta Brain Research Center","RECRUITING","Barcelona","Catalonia","08005","Spain","ES",{"type":44,"coordinates":45},"Point",[46,47],2.15899,41.38879,{"lat":47,"lon":46},[50,52,53,54],{"name":27,"role":28,"phone":51,"phoneExt":10,"email":30},"+34933160990",{"name":32,"role":28,"phone":51,"phoneExt":10,"email":33},{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Juan Domingo Gispert, PhD","SUB_INVESTIGATOR",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60,62],{"name":61,"class":6},"Hospital Clinic of Barcelona",{"name":63,"class":64},"General Electric","INDUSTRY","100261699","brain-characterization-of-amyloid-protein-and-glucose-metabolism-of-alfa-project-participants-100261699",false,"NCT02685969","Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants","Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.","Inclusion Criteria:\n\n* To sign the study informed consent form approved by the corresponding authorities.\n* Men and women enrolled in the ALFA project (STUDY 45-65 FPM\u002F2012).\n* Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion.\n* Cognition within psychometrically normal ranges: MMSE (Mini Mental State Examination ≥26 and Semantic Fluency (animals) ≥12.\n* Score of 0 in the CDR scale (Clinical Dementia Rating).\n* Good knowledge of the language and being literate.\n* Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.\n\nExclusion Criteria:\n\n* Present cognitive impairment.\n* Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia or bipolar disorder.\n* Individuals with visual and\u002For hearing impairment.\n* History of encephalitis, ictus or seizures excluding feverish convulsions during childhood.\n* Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis\u002Fbrain cancer) as verified by magnetic resonance imaging (MRI).\n* Any contraindication to MRI acquisition, (i.e., metal implants) or phobia to performing the scan as determined by the onsite physician.\n* Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and\u002For administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study.",true,"ALL","45 Years","75 Years",{"count":77,"type":78},570,"ESTIMATED","OBSERVATIONAL","Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.\n\nCross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project.\n\nStudy without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease).\n\nEach study candidate will be selected from the ALFA project (STUDY 45-65 FPM\u002F2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study.\n\nAfter signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed",[82],"Alzheimer's Disease",[84,85],"Prevention","Positron Emission Tomography","2025-05-27",{"date":88,"type":89},"2025-05-31","ACTUAL",{"date":91,"type":89},"2017-03-01",{"date":93,"type":78},"2027-12-31",{"name":5,"class":6},1]